Literature DB >> 27543617

Augmentation of Circulating Follicular Helper T Cells and Their Impact on Autoreactive B Cells in Myasthenia Gravis.

Cun-Jin Zhang1, Ye Gong2, Wenli Zhu2, Yuan Qi2, Chun-Sheng Yang2, Ying Fu2, Guoqiang Chang2, Yujing Li2, Samuel Shi3, Kristofer Wood3, Shafeeq Ladha3, Fu-Dong Shi1, Qiang Liu4, Yaping Yan5.   

Abstract

Myasthenia gravis (MG) is a chronic humoral immunity-mediated autoimmune disorder of the neuromuscular junction characterized by muscle weakness. Follicular helper T (Tfh) cells may be the key Th cell subset that promotes MG development, as their major function is helping B cell activation and Ab production. Aberrance of thymus-derived Tfh cells might be implicated in autoimmune diseases including MG; just how circulating Tfh cells, especially those from patients with a normal thymus, contribute to MG pathogenesis remains to be uncovered. In this article, we characterize a population of circulating CD4(+)CXCR5(+)PD-1(+) Tfh cells in ocular and generalized MG patients without thymic abnormalities and demonstrate that the circulating Tfh cells are significantly enriched in generalized MG patients but not in ocular MG patients compared with healthy subjects, whereas a proportion of follicular regulatory T cells decreased in MG patients. In addition, the frequency of plasma cells and B cells was higher and the serum levels of IL-6/IL-21 were also elevated in these MG patients. The activated Tfh1 and Tfh17 in Tfh cells are the major source for IL-21 production in MG patients. A strong correlation between Tfh cells and the plasma cell frequency and anti-acetylcholine receptor Ab titers was evident in generalized MG patients. In particular, we found that Tfh cells derived from MG patients promoted B cells to produce Abs in an IL-21 signaling-dependent manner. Collectively, our results suggest that circulating Tfh cells may act on autoreactive B cells and thus contribute to the development of MG in patients without thymic abnormalities.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Year:  2016        PMID: 27543617     DOI: 10.4049/jimmunol.1500725

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

Review 1.  Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.

Authors:  Grayson Beecher; Brendan Nicholas Putko; Amanda Nicole Wagner; Zaeem Azfer Siddiqi
Journal:  Drugs       Date:  2019-03       Impact factor: 9.546

Review 2.  B cells in the pathophysiology of myasthenia gravis.

Authors:  John S Yi; Jeffrey T Guptill; Panos Stathopoulos; Richard J Nowak; Kevin C O'Connor
Journal:  Muscle Nerve       Date:  2017-09-30       Impact factor: 3.217

3.  Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients.

Authors:  Yingkai Li; Jeffrey T Guptill; Melissa A Russo; Janice M Massey; Vern C Juel; Lisa D Hobson-Webb; James F Howard; Manisha Chopra; Weibin Liu; John S Yi
Journal:  Exp Neurol       Date:  2018-11-22       Impact factor: 5.330

4.  The effect of interleukin (IL)-21 and CD4+ CD25++ T cells on cytokine production of CD4+ responder T cells in patients with myasthenia gravis.

Authors:  M Alahgholi-Hajibehzad; H Durmuş; F Aysal; Y Gülşen-Parman; P Oflazer; F Deymeer; G Saruhan-Direskeneli
Journal:  Clin Exp Immunol       Date:  2017-07-28       Impact factor: 4.330

5.  Reduced plasmablast frequency is associated with seronegative myasthenia gravis.

Authors:  Jeffrey T Guptill; Richard Barfield; Cliburn Chan; Melissa A Russo; Doug Emmett; Shruti Raja; Janice M Massey; Vern C Juel; Lisa D Hobson-Webb; Karissa L Gable; Natalia Gonzalez; Alex Hammett; James F Howard; Manisha Chopra; Henry J Kaminski; Zaeem A Siddiqi; Mattingly Migdal; John S Yi
Journal:  Muscle Nerve       Date:  2020-12-24       Impact factor: 3.217

6.  Immune Skew of Circulating Follicular Helper T Cells Associates With Myasthenia Gravis Severity.

Authors:  Shinji Ashida; Hirofumi Ochi; Mio Hamatani; Chihiro Fujii; Kimitoshi Kimura; Yoichiro Okada; Yuichiro Hashi; Kazuyuki Kawamura; Hideki Ueno; Ryosuke Takahashi; Toshiki Mizuno; Takayuki Kondo
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-01-12

7.  Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signature.

Authors:  Bettina Schreiner; Burkhard Becher; Florian Ingelfinger; Sinduya Krishnarajah; Michael Kramer; Sebastian G Utz; Edoardo Galli; Mirjam Lutz; Pascale Zwicky; Ayse U Akarca; Nicole Puertas Jurado; Can Ulutekin; David Bamert; Corinne C Widmer; Luca Piccoli; Federica Sallusto; Nicolás G Núñez; Teresa Marafioti; Didier Schneiter; Isabelle Opitz; Antonio Lanzavecchia; Hans H Jung; Donatella De Feo; Sarah Mundt
Journal:  Acta Neuropathol       Date:  2021-03-28       Impact factor: 17.088

8.  Altered distributions in circulating follicular helper and follicular regulatory T cells accountable for imbalanced cytokine production in multiple sclerosis.

Authors:  R Haque; Y Kim; K Park; H Jang; S Y Kim; H Lee; H J Kim
Journal:  Clin Exp Immunol       Date:  2021-04-25       Impact factor: 5.732

Review 9.  Roles of cytokines and T cells in the pathogenesis of myasthenia gravis.

Authors:  A Uzawa; S Kuwabara; S Suzuki; T Imai; H Murai; Y Ozawa; M Yasuda; Y Nagane; K Utsugisawa
Journal:  Clin Exp Immunol       Date:  2020-12-03       Impact factor: 5.732

10.  IL-21 enhances STAT3/Blimp-1 signaling pathway in B cells and contributes to plasma cell differentiation in newly diagnosed patients with myasthenia gravis.

Authors:  Yanan Xu; Xiaoyu Huang; Fengzhan Li; Tan Liu; Tingting Yang; Fei Chen; Jie Zhu; Meng Pan; Yong Zhang; Yuzhong Wang; Linlin Fu; Chenghua Xiao; Deqin Geng
Journal:  Immunol Res       Date:  2020-11-03       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.